The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer - PubMed (original) (raw)

. 2004 Oct;204(2):159-66.

doi: 10.1002/path.1609.

Affiliations

• PMID: 15378487
• DOI: 10.1002/path.1609

The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer

Barbara Comuzzi et al. J Pathol. 2004 Oct.

Abstract

The androgen receptor co-activator CREB (cAMP-response element binding protein)-binding protein (CBP) enhances androgen receptor activity after stimulation by androgenic hormones and androgen receptor antagonists. The aim of the present study was to investigate the regulation of CBP expression by steroid and peptide hormones in prostate cancer. For this purpose, LNCaP cells were treated with the synthetic androgen methyltrienolone (R1881), epidermal growth factor, insulin-like growth factor-I or interleukin-6 (IL-6). CBP protein and mRNA expression were studied by western blotting and real-time PCR, respectively. CBP expression was also investigated in tissue specimens obtained from 26 patients with therapy-resistant carcinoma of the prostate. In LNCaP cells, CBP protein was down-regulated by R1881 or IL-6. The non-steroidal anti-androgen bicalutamide antagonized the effects of R1881 and the Janus kinase inhibitor AG 490 reversed the effects of IL-6. In contrast, neither R1881 nor IL-6 caused any effect on CBP expression in the PC-3 cell line. In LNCaP cells, the inhibition of CBP expression by R1881 or IL-6 was also observed at the mRNA level. CBP protein was detected in all 26 specimens by immunohistochemistry. The results suggest that up-regulation of CBP during androgen ablation may be relevant to the failure of endocrine therapy in patients with prostate carcinoma.

PubMed Disclaimer

Similar articles

• Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
  Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, Belfiore A. Pandini G, et al. Cancer Res. 2005 Mar 1;65(5):1849-57. doi: 10.1158/0008-5472.CAN-04-1837. Cancer Res. 2005. PMID: 15753383
• Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
  Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Culig Z, et al. Br J Cancer. 1999 Sep;81(2):242-51. doi: 10.1038/sj.bjc.6690684. Br J Cancer. 1999. PMID: 10496349 Free PMC article.
• The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and anti-androgen-induced androgen receptor function.
  Comuzzi B, Lambrinidis L, Rogatsch H, Godoy-Tundidor S, Knezevic N, Krhen I, Marekovic Z, Bartsch G, Klocker H, Hobisch A, Culig Z. Comuzzi B, et al. Am J Pathol. 2003 Jan;162(1):233-41. doi: 10.1016/S0002-9440(10)63814-X. Am J Pathol. 2003. PMID: 12507906 Free PMC article.
• Expression and function of androgen receptor coactivators in prostate cancer.
  Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Culig Z, et al. J Steroid Biochem Mol Biol. 2004 Nov;92(4):265-71. doi: 10.1016/j.jsbmb.2004.10.003. Epub 2004 Dec 19. J Steroid Biochem Mol Biol. 2004. PMID: 15663989 Review.
• Androgen receptor co-activators in the regulation of cellular events in prostate cancer.
  Culig Z, Santer FR. Culig Z, et al. World J Urol. 2012 Jun;30(3):297-302. doi: 10.1007/s00345-011-0797-6. Epub 2011 Nov 22. World J Urol. 2012. PMID: 22105110 Review.

Cited by

• Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.
  Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, McEwan IJ, Plymate S, Sadar MD. Yang YC, et al. Clin Cancer Res. 2016 Sep 1;22(17):4466-77. doi: 10.1158/1078-0432.CCR-15-2901. Epub 2016 May 2. Clin Cancer Res. 2016. PMID: 27140928 Free PMC article.
• EP300/CREBBP acetyltransferase inhibition limits steroid receptor and FOXA1 signaling in prostate cancer cells.
  Huttunen J, Aaltonen N, Helminen L, Rilla K, Paakinaho V. Huttunen J, et al. Cell Mol Life Sci. 2024 Apr 2;81(1):160. doi: 10.1007/s00018-024-05209-z. Cell Mol Life Sci. 2024. PMID: 38564048 Free PMC article.
• MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.
  Nilsson EM, Laursen KB, Whitchurch J, McWilliam A, Ødum N, Persson JL, Heery DM, Gudas LJ, Mongan NP. Nilsson EM, et al. Oncotarget. 2015 Nov 3;6(34):35710-25. doi: 10.18632/oncotarget.5958. Oncotarget. 2015. PMID: 26461474 Free PMC article.
• Spongian diterpenoids inhibit androgen receptor activity.
  Yang YC, Meimetis LG, Tien AH, Mawji NR, Carr G, Wang J, Andersen RJ, Sadar MD. Yang YC, et al. Mol Cancer Ther. 2013 May;12(5):621-31. doi: 10.1158/1535-7163.MCT-12-0978. Epub 2013 Feb 26. Mol Cancer Ther. 2013. PMID: 23443807 Free PMC article.
• Differential regulation of steroid nuclear receptor coregulator expression between normal and neoplastic prostate epithelial cells.
  Heemers HV, Schmidt LJ, Kidd E, Raclaw KA, Regan KM, Tindall DJ. Heemers HV, et al. Prostate. 2010 Jun 15;70(9):959-70. doi: 10.1002/pros.21130. Prostate. 2010. PMID: 20166126 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information